한글목차

세계의 펩타이드 CXO 시장 미래는 제약회사나 바이오테크놀러지 기업·연구기관 시장에 기회가 있어 유망시되고 있습니다. 세계의 펩타이드 CXO 시장은 2025년부터 2031년에 걸쳐 CAGR 10.6%를 나타낼 것으로 예측됩니다. 이 시장의 주요 촉진요인은 맞춤형 의료에 대한 수요가 증가하고, 만성 질환의 유병률이 증가하고, 표적 치료에 대한 주목 증가입니다.

• Lucintel은 유형별로 CMO/CDMO가 예측 기간 동안 높은 성장을 이룰 것으로 예측했습니다.
• 용도별로는 바이오테크놀러지 기업·연구기관이 높은 성장을 이룰 전망입니다.
• 지역별로는 APAC이 예측 기간 동안 가장 높은 성장이 예상됩니다.

150페이지 이상의 종합적인 보고서를 통해 비즈니스 의사 결정에 도움이 되는 귀중한 인사이트를 제공합니다. 몇 가지 인사이트를 포함하는 샘플 다이어그램이 아래에 나와 있습니다.

펩타이드 CXO 시장 새로운 동향

펩타이드 CXO 시장은 바이오 의약품 업계의 요구 변화와 펩타이드 합성 및 제조 기술의 혁신에 대응하는 다양한 현저한 동향의 영향을 받고 있습니다.

• 복잡한 변형된 펩타이드에 대한 요구 증가 : 긴 펩타이드, 고리형 펩타이드, PEG화, 지질화, 글리코실화와 같은 화학적 변형과 같은 보다 복잡한 펩타이드에 대한 수요가 증가하는 경향이 있습니다. 이러한 변형은 펩타이드의 안정성, 생물학적 이용능력, 표적에 대한 특이성을 향상시켜 고도의 합성·변형 능력을 가진 CXO를 요구하게 됩니다.
• 자동화 및 높은 처리량 합성 채택 확대 : 증가하는 수요에 대응하고 합성 기간을 단축하기 위해 자동화 및 고처리량 펩타이드 합성 플랫폼의 채택이 확대되고 있습니다. 이러한 기술은 여러 펩타이드의 병렬 합성을 가능하게 하고, 의약품 및 조사 방법을 가속화하는 동시에 효율을 향상시키고 비용을 절감합니다.
• 녹색으로 지속가능한 펩타이드 합성 : 지속가능성에 대한 세계적인 관심 증가는 보다 친환경적이고 지속가능한 펩타이드 합성 과정으로의 전환을 촉진하고 있습니다. 여기에는 대체 용매의 사용, 폐기물 최소화, 보다 효과적인 합성 및 정제 전략의 채용이 포함되어 펩타이드 생산에 있어서 환경 부하를 감소시킵니다.
• 정교한 분석법의 도입 : 순수한 펩타이드의 필요성으로부터 완전한 특성화 및 품질 보증을 위해 고급 분석법을 도입해야 합니다. 여기에는 고속 액체 크로마토그래피(HPLC), 질량 분석(MS), 핵자기 공명(NMR) 분광법이 포함되어 1개의 펩타이드의 순도, 동일성 및 구조의 무결성을 검증합니다.
• GMP 등급의 펩타이드 제조 스케일 업 : 펩타이드 치료제의 임상시험 및 상업화가 진행됨에 따라, GMP(의약품의 제조 관리 및 품질 관리에 관한 기준) 등급의 펩타이드 제조 능력의 대폭적인 스케일 업이 이루어지고 있습니다. CXO는 인간 임상시험 및 상업용 의약품에 사용하기 위해 엄격한 규제 기준을 준수해야 하는 펩타이드를 공급하기 위한 인프라와 능력을 구축하고 있습니다.

이러한 새로운 동향은 합성기술의 혁신을 촉진하고, 생산가능한 펩타이드의 범위를 넓히고, 지속가능성을 강조하고, 품질관리를 개선하고, GMP 생산능력을 증강함으로써, 펩타이드 CXO 시장을 누적적으로 변화시켜, 확대하는 펩타이드 치료제의 영역을 뒷받침하고 있습니다.

펩타이드 CXO 시장 최근 동향

펩타이드 CXO 시장에서의 최신 발전은 합성, 변형, 제조 기술의 지속적인 발전과 더불어 품질과 규정 준수에 대한 관심 증가를 반영합니다.

• 신규 고상 합성 수지 및 링커의 진보 : 고상 합성의 진보는 펩타이드의 수율과 순도를 높이고 어려운 펩타이드 서열의 합성을 단순화하는 새로운 수지 및 링커의 설계를 포함합니다.
• 연속 흐름 펩타이드 합성 개발 : 연속 흐름 합성은 보다 효율적이고 반응 제어, 순도, 비용 효율적인 펩타이드 합성의 개선된 스케일 업 공정으로 뒷받침됩니다.
• 효소 펩타이드 합성의 능력 향상 : 효소적 펩타이드 합성은 높은 선택성과 침습적인 화학물질의 사용 측면에서 잠재적으로 비용이 낮기 때문에 개별 펩타이드 서열에 대한 보다 친환경적인 접근법이 되고 있습니다.
• 펩타이드 설계 및 최적화에서 인공지능의 통합 : AI 및 머신러닝 기반 알고리즘은 펩타이드의 거동 예측, 합성 프로토콜의 합리화, 표적 특성을 가진 새로운 펩타이드 서열의 설계에 점점 활용되고 있습니다.
• 품질 시스템 및 규정 준수의 중요성 : 펩타이드의 CXO는 GMP와 같은 매우 엄격한 규제 요건을 준수하고 연구 및 치료를 위해 합성된 펩타이드의 안전성과 효능을 보장하는 효과적인 품질 관리 시스템의 확립에 더욱 중점을 두고 있습니다.

이러한 본질적인 진보는 보다 복잡한 펩타이드를 보다 효율적으로, 보다 높은 순도로 합성하는 것을 용이하게 하고, 지속가능한 프로세스의 실천을 장려하고, 펩타이드 설계에 컴퓨팅 기술을 활용하고, 목적에 따라 엄격한 품질 기준을 준수함으로써 펩타이드 CXO 시장에 혁명을 가져오고 있습니다.

목차

제1장 주요 요약

제2장 세계의 펩타이드 CXO 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• PESTLE 분석
• 특허 분석
• 규제 환경
• 업계의 성장 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시 경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 펩타이드 CXO 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 펩타이드 CXO 시장 : 유형별
  • CRO : 동향과 예측(2019-2031년)
  • CMO/CDMO : 동향과 예측(2019-2031년)
• 세계의 펩타이드 CXO 시장 : 용도별
  • 제약회사 : 동향과 예측(2019-2031년)
  • 바이오테크놀러지 기업 및 연구기관 : 동향과 예측(2019-2031년)
  • 기타 : 동향과 예측(2019-2031년)

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 펩타이드 CXO 시장 : 지역별
• 북미의 펩타이드 CXO 시장
• 유럽의 펩타이드 CXO 시장
• 아시아태평양의 펩타이드 CXO 시장
• 기타 지역의 펩타이드 CXO 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 펩타이드 CXO 시장 성장 기회 : 유형별
  • 세계의 펩타이드 CXO 시장 성장 기회 : 용도별
  • 세계의 펩타이드 CXO 시장 성장 기회 : 지역별
• 세계의 펩타이드 CXO 시장 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 펩타이드 CXO 시장 능력 확대
  • 세계의 펩타이드 CXO 시장 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• Polypeptide
• Bachem
• LONZA
• Bicycle
• Pepscan
• JPT Peptide
• WuXi AppTec
• Asymchem
• Jiangsu Sinopep-Allsino Biopharmaceutical
• Chinese Peptide Company

영문목차

The future of the global peptide CXO market looks promising with opportunities in the pharmaceutical company and biotech company & research institution markets. The global peptide CXO market is expected to grow with a CAGR of 10.6% from 2025 to 2031. The major drivers for this market are the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and the growing focus on targeted therapies.

• Lucintel forecasts that, within the type category, CMO/CDMO is expected to witness higher growth over the forecast period.
• Within the application category, biotech company & research institution is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Peptide CXO Market

The peptide CXO market is influenced by various prominent trends that address the changing needs of the biopharmaceutical industry as well as innovation in peptide synthesis and manufacturing technology.

• Growing Need for Complex and Modified Peptides: The trend is growing demand for peptides with greater complexity, such as longer lengths, cyclic peptides, and chemical modifications such as PEGylation, lipidation, and glycosylation. These modifications provide improved peptide stability, bioavailability, and specificity to targets, leading to the requirement for CXOs with sophisticated synthesis and modification capacity.
• Growing Adoption of Automation and High-Throughput Synthesis: To meet the increasing demand and reduce synthesis timelines, there is a growing adoption of automated and high-throughput peptide synthesis platforms. These technologies enable the parallel synthesis of multiple peptides, accelerating drug discovery and research processes while improving efficiency and reducing costs.
• Green and Sustainable Peptide Synthesis: The world's growing interest in sustainability is compelling the world to move toward greener and more sustainable peptide synthesis processes. This involves using alternative solvents, minimizing waste generation, and employing more effective synthesis and purification strategies to lower the environmental burden of peptide production.
• Incorporation of Sophisticated Analytical Methods: The need for pure peptides requires incorporation of sophisticated analytical methods for full characterization and quality assurance. This involves high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy to validate 1 peptide purity, identity, and structural integrity.
• GMP-Grade Peptide Manufacturing Scale-Up: As the number of peptide therapeutics advances into clinical trials and commercializes, there is a vast scale-up of GMP (Good Manufacturing Practice)-grade peptide manufacturing capacity. CXOs are building infrastructure and capability to supply peptides that must adhere to demanding regulatory standards for use in human clinical trials and commercial drug products.

These new trends are cumulatively transforming the peptide CXO market by encouraging innovation in synthesis technologies, broadening the extent of peptides that can be produced, highlighting sustainability, improving quality control, and ramping up GMP production capacity to underpin the expanding space of peptide therapeutics.

Recent Developments in the Peptide CXO Market

Latest advances in the market for peptide CXO reflect continuing progress in synthesis, modification, and manufacturing technology, as well as growing concern with quality and regulatory compliance.

• Advances in Novel Solid-Phase Synthesis Resins and Linkers: Advances in solid-phase synthesis involve the design of new resins and linkers that enhance peptide yield and purity and simplify the synthesis of difficult peptide sequences.
• Developments in Continuous Flow Peptide Synthesis: Continuous flow synthesis is finding favor as an improved and scale-up process of peptide synthesis that is more efficient, with merits of reaction control, purity, and cost effectiveness.
• Pushing the Capabilities of Enzymatic Peptide Synthesis: Enzymatic peptide synthesis is becoming the more environmentally friendly approach for individual peptide sequences due to high selectivity and being potentially less costly in terms of the use of aggressive chemicals.
• Artificial Intelligence Integration in Peptide Design and Optimization: AI and machine learning-based algorithms are being increasingly utilized to predict peptide behavior, streamline synthesis protocols, and design new peptide sequences with target properties.
• Greater Emphasis on Quality Systems and Regulatory Compliance: Peptide CXOs are putting more emphasis on compliance with highly stringent regulatory requirements, e.g., GMP, and on the establishment of effective quality management systems that guarantee the safety and efficacy of peptides synthesized for research and therapeutic use.

These essential advancements are revolutionizing the peptide CXO market by facilitating the synthesis of more complicated peptides more efficiently and with greater purity, encouraging sustainable process practices, utilizing computational technologies for peptide design, and adhering to stringent standards of quality for different purposes.

Strategic Growth Opportunities in the Peptide CXO Market

The peptide CXO market presents tremendous strategic growth opportunities across a broad spectrum of applications in the life sciences and pharmaceutical sectors.

• Therapeutic Peptide Development: The growing number of peptide-based drugs under development for different diseases, such as cancer, diabetes, and cardiovascular disease, is a significant growth opportunity for CXOs offering bespoke synthesis and GMP manufacturing services.
• Peptide-Based Diagnostics: Diagnostic applications of peptides, including imaging agents and biosensors, are increasing, providing opportunities for CXOs to design specialized peptides with particular labeling and targeting capabilities.
• Cosmetic Peptides: Increasing demand for peptides in the cosmetics market for anti-aging and skin-improving products provides a niche market for CXOs who can produce high-purity cosmetic-grade peptides.
• Agrochemical Peptides: Scientific studies of peptide-based agrochemicals, including crop defense agents and plant growth promoters, offer a promising future area for growth by CXOs who are experts in the synthesis of peptides on a large scale.
• Peptides for Basic Research: Educational and research organizations need an extensive range of custom peptides to support basic investigations in biology, biochemistry, and materials science, thus providing a steady need for CXO services.

These strategic expansion opportunities in the therapeutic development, diagnostics, cosmetics, agrochemicals, and basic research areas demonstrate the widespread and increasing uses of synthetic peptides and fuel demand for expert CXO services.

Peptide CXO Market Driver and Challenges

The peptide CXO market is affected by a mix of drivers and challenges that influence its development and transformation in the wider life sciences sector.

The factors responsible for driving the peptide CXO market include:

1. Expanding Pipeline of Peptide Therapeutics: The rising pipeline of peptide drug candidates in clinical and preclinical development is one of the major drivers for peptide synthesis and manufacturing services demand.

2. Benefits of Peptide Therapeutics: Peptides have some benefits as therapeutics, such as high specificity, reduced toxicity versus small molecules, and targeting intracellular interactions, which is propelling their growing use.

3. New Technology Developments in Peptide Synthesis: Progressive development in solid-phase and liquid-phase peptide synthesis and introduction of novel technologies such as continuous flow and enzymatic synthesis is allowing for more elaborate and cost-effective peptides to be synthesized.

4. Expanding Funding in Life Science Research: Escalating private and public research investment in biotechnology and pharmaceutical research is fueling the use of custom peptides as tools in research and as leads in drugs.

5. Growth of the Biotechnology and Pharmaceutical Sectors in Emerging Economies: The high-speed development of the biopharmaceutical industry in countries such as China and India is opening up new opportunities for peptide CXOs to offer their services to local firms.

Challenges in the peptide CXO market are:

1. Technical Difficulty of Synthesizing Long and Altered Peptides: The technical difficulty of synthesizing longer peptide sequences and those with complex alterations can pose significant challenges, calling for expert technical skills and facilities.

2. High Peptide Synthesis Costs: The expense of peptide synthesis, particularly for peptides with modifications or those that must be synthesized under GMP-grade conditions, can be a prohibitive factor for certain research studies and smaller firms.

3. Regulatory Hurdles for Therapeutic Peptides: The regulatory environment for peptide therapeutics is complicated, with CXOs needing to comply with rigorous quality and manufacturing guidelines, which are expensive to put in place and maintain.

The CXO peptide market is witnessing robust growth fueled by the growing pipeline of peptide therapeutics, the intrinsic benefits of peptides as medicines, improved synthesis technologies, rising funding for research, and the rise of biopharma in emerging economies. Nevertheless, issues pertaining to synthesis complexity and cost, stringent regulation, competition from internal capabilities, and manufacturing scalability must be resolved in order for the market to maintain its success and grow further.

List of Peptide CXO Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide CXO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peptide CXO companies profiled in this report include-

• Polypeptide
• Bachem
• LONZA
• Bicycle
• Pepscan
• JPT Peptide
• WuXi AppTec
• Asymchem
• Jiangsu Sinopep-Allsino Biopharmaceutical
• Chinese Peptide Company

Peptide CXO Market by Segment

The study includes a forecast for the global peptide CXO market by type, application, and region.

Peptide CXO Market by Type [Value from 2019 to 2031]:

• CRO
• CMO/CDMO

Peptide CXO Market by Application [Value from 2019 to 2031]:

• Pharmaceutical Companies
• Biotech Companies & Research Institutions
• Others

Peptide CXO Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Peptide CXO Market

The name "Peptide CXO" generally denotes custom peptide synthesis and production services provided to pharmaceutical and biotechnology firms, academic institutions, and research institutions. Such services address the expanding need for synthetic peptides in drug discovery, diagnostics, and basic research. Current trends in this market are defined by technological advances in peptide synthesis technologies, rising demand for complex and modified peptides, and the geographical spread of service providers. The demand for high-quality, cost-effective, and scalable peptide manufacturing is fueling innovation in this niche industry in many global regions.

• United States: The US market for peptide CXO is mature, competitive, and highly focused on innovation and quality. Recent trends include the use of cutting-edge solid-phase peptide synthesis (SPPS) methods for the production of complex peptides and the incorporation of automation and high-throughput technologies. Increasing demand for peptide modifications like cyclization and PEGylation, as well as GMP-grade peptide production for clinical studies, is also being witnessed.
• China: China's CXO market for peptides is growing at a fast pace, fueled by the growing biopharmaceutical industry and rising research activity. Local CXOs are improving their capacity to synthesize longer and more complex peptides, as well as providing more varied modifications. Advances have included upgrading quality control standards and rising emphasis on international collaborations and GMP compliance to support global customers.
• Germany: Germany's CXO peptide market is dominated by a research-driven innovation and high-quality production focus. Recent trends have included the development of liquid-phase peptide synthesis (LPPS) for specialized use and new purification methods. There is also great importance placed on tailored peptide design and synthesis for research in academia and industry, as well as GMP-grade manufacture for use in the clinic.
• India: The Indian peptide CXO market is becoming a budget-friendly option for peptide synthesis services. Latest news includes more and more local CXOs establishing capacity in solid-phase and liquid-phase synthesis. There is an increasing emphasis on following international standards of quality and offering peptide modifications and GMP-grade manufacturing capabilities to serve both domestic and foreign research and pharmaceutical requirements.
• Japan: The Japanese peptide CXO market features a high value placed on top-quality and customized peptide synthesis. New trends encompass the development in synthesizing complex structure and modification peptides, mainly for therapeutic usage. Innovative techniques for peptide purification and analysis as well as GMP-compliant manufacturing for pharma development and clinical trials also feature.

Features of the Global Peptide CXO Market

• Market Size Estimates: Peptide CXO market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Peptide CXO market size by type, application, and region in terms of value ($B).
• Regional Analysis: Peptide CXO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the peptide CXO market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide CXO market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the peptide CXO market by type (CRO and CMO/CDMO), application (pharmaceutical companies, biotech companies & research institutions, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peptide CXO Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: PESTLE Analysis
• 2.4: Patent Analysis
• 2.5: Regulatory Environment
• 2.6: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Peptide CXO Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Peptide CXO Market by Type
  • 3.3.1: CRO: Trends and Forecast (2019 to 2031)
  • 3.3.2: CMO/CDMO: Trends and Forecast (2019 to 2031)
• 3.4: Global Peptide CXO Market by Application
  • 3.4.1: Pharmaceutical Companies: Trends and Forecast (2019 to 2031)
  • 3.4.2: Biotech Companies & Research Institutions: Trends and Forecast (2019 to 2031)
  • 3.4.3: Others: Trends and Forecast (2019 to 2031)

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Peptide CXO Market by Region
• 4.2: North American Peptide CXO Market
  • 4.2.1: North American Market by Type: CRO and CMO/CDMO
  • 4.2.2: North American Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
  • 4.2.3: The United States Peptide CXO Market
  • 4.2.4: Mexican Peptide CXO Market
  • 4.2.5: Canadian Peptide CXO Market
• 4.3: European Peptide CXO Market
  • 4.3.1: European Market by Type: CRO and CMO/CDMO
  • 4.3.2: European Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
  • 4.3.3: German Peptide CXO Market
  • 4.3.4: French Peptide CXO Market
  • 4.3.5: Spanish Peptide CXO Market
  • 4.3.6: Italian Peptide CXO Market
  • 4.3.7: The United Kingdom Peptide CXO Market
• 4.4: APAC Peptide CXO Market
  • 4.4.1: APAC Market by Type: CRO and CMO/CDMO
  • 4.4.2: APAC Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
  • 4.4.3: Japanese Peptide CXO Market
  • 4.4.4: Indian Peptide CXO Market
  • 4.4.5: Chinese Peptide CXO Market
  • 4.4.6: South Korean Peptide CXO Market
  • 4.4.7: Indonesian Peptide CXO Market
• 4.5: ROW Peptide CXO Market
  • 4.5.1: ROW Market by Type: CRO and CMO/CDMO
  • 4.5.2: ROW Market by Application: Pharmaceutical Companies, Biotech Companies & Research Institutions, and Others
  • 4.5.3: Middle Eastern Peptide CXO Market
  • 4.5.4: South American Peptide CXO Market
  • 4.5.5: African Peptide CXO Market

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Peptide CXO Market by Type
  • 6.1.2: Growth Opportunities for the Global Peptide CXO Market by Application
  • 6.1.3: Growth Opportunities for the Global Peptide CXO Market by Region
• 6.2: Emerging Trends in the Global Peptide CXO Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Peptide CXO Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide CXO Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Polypeptide
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.2: Bachem
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.3: LONZA
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.4: Bicycle
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.5: Pepscan
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.6: JPT Peptide
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.7: WuXi AppTec
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.8: Asymchem
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.9: Jiangsu Sinopep-Allsino Biopharmaceutical
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.10: Chinese Peptide Company
  • Company Overview
  • Peptide CXO Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing